CA3100319A1 - Matrix metalloproteinase (mmp) inhibitors and methods of use thereof - Google Patents
Matrix metalloproteinase (mmp) inhibitors and methods of use thereof Download PDFInfo
- Publication number
- CA3100319A1 CA3100319A1 CA3100319A CA3100319A CA3100319A1 CA 3100319 A1 CA3100319 A1 CA 3100319A1 CA 3100319 A CA3100319 A CA 3100319A CA 3100319 A CA3100319 A CA 3100319A CA 3100319 A1 CA3100319 A1 CA 3100319A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- mixture
- mmol
- hydrogen
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671753P | 2018-05-15 | 2018-05-15 | |
| US62/671,753 | 2018-05-15 | ||
| PCT/US2019/032127 WO2019222154A1 (en) | 2018-05-15 | 2019-05-14 | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3100319A1 true CA3100319A1 (en) | 2019-11-21 |
Family
ID=66690981
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3100319A Pending CA3100319A1 (en) | 2018-05-15 | 2019-05-14 | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
| CA3100320A Pending CA3100320A1 (en) | 2018-05-15 | 2019-05-14 | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3100320A Pending CA3100320A1 (en) | 2018-05-15 | 2019-05-14 | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US12258335B1 (https=) |
| EP (4) | EP4349332A3 (https=) |
| JP (4) | JP7344959B2 (https=) |
| KR (3) | KR102861502B1 (https=) |
| CN (3) | CN119462623A (https=) |
| AU (3) | AU2019269409B2 (https=) |
| BR (1) | BR112020023269A2 (https=) |
| CA (2) | CA3100319A1 (https=) |
| DK (2) | DK3793992T3 (https=) |
| ES (2) | ES2978192T3 (https=) |
| FI (2) | FI3793995T3 (https=) |
| HU (2) | HUE066627T2 (https=) |
| LT (1) | LT3793995T (https=) |
| MY (1) | MY199200A (https=) |
| PL (1) | PL3793995T3 (https=) |
| PT (2) | PT3793992T (https=) |
| SG (2) | SG11202011316RA (https=) |
| SI (1) | SI3793995T1 (https=) |
| TW (3) | TWI798435B (https=) |
| WO (2) | WO2019222154A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10532102B2 (en) | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| KR102861502B1 (ko) * | 2018-05-15 | 2025-09-18 | 포시 파마슈티컬스 유에스에이 인코포레이티드 | 기질 금속단백분해효소 (mmp) 억제제 및 이의 사용 방법 |
| CN115667227B (zh) | 2019-11-14 | 2024-11-01 | 逸达生物科技股份有限公司 | 基质金属蛋白酶(mmp)抑制剂及其使用方法 |
| JP2024520818A (ja) * | 2021-06-08 | 2024-05-24 | フォアシー ファーマシューティカルズ カンパニー リミテッド | 急性呼吸促迫症候群を処置するためのｍｍｐ阻害薬の使用 |
| EP4351566A4 (en) * | 2021-06-08 | 2025-04-23 | Foresee Pharmaceuticals USA, Inc. | SAFE ADMINISTRATION OF MMP-12 INHIBITOR |
| WO2023110473A1 (en) | 2021-12-14 | 2023-06-22 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
| EP4198033A1 (en) | 2021-12-14 | 2023-06-21 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2482618A1 (fr) | 1980-05-16 | 1981-11-20 | Inst Corps Gras Iterg | Procede de conjugaison catalytique de corps gras polyinsatures, produits obtenus et application |
| US6352976B1 (en) | 1998-12-31 | 2002-03-05 | Aventis Pharmaceuticals Inc. | Selective inhibitors of MMP-12 |
| AU1817700A (en) | 1998-12-31 | 2000-07-24 | Aventis Pharmaceuticals Inc. | 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12 |
| AU4882101A (en) | 2000-04-28 | 2001-11-12 | Shionogi & Co., Ltd. | Mmp-12 inhibitors |
| SE0100903D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| KR20030082990A (ko) * | 2001-03-15 | 2003-10-23 | 아스트라제네카 아베 | 메탈로프로테이나제 억제제 |
| CA2447475A1 (en) | 2001-05-25 | 2002-12-05 | Chu-Biao Xue | Hydantion derivatives as inhibitors of matrix metalloproteinases |
| EP1394159A1 (fr) | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| US7041693B2 (en) | 2002-10-04 | 2006-05-09 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| US7132432B2 (en) | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
| DK1789036T3 (da) * | 2004-08-19 | 2011-06-27 | Quest Pharmaceutical Services | 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dion og analoger som inhibitorer af makrofagelastase |
| JP5357365B1 (ja) | 2011-12-21 | 2013-12-04 | パナソニック株式会社 | データ処理装置、データ送信装置、データ処理システム、データ処理方法、及び、データ送信方法 |
| KR102861502B1 (ko) | 2018-05-15 | 2025-09-18 | 포시 파마슈티컬스 유에스에이 인코포레이티드 | 기질 금속단백분해효소 (mmp) 억제제 및 이의 사용 방법 |
-
2019
- 2019-05-14 KR KR1020207035504A patent/KR102861502B1/ko active Active
- 2019-05-14 CN CN202411619226.XA patent/CN119462623A/zh active Pending
- 2019-05-14 ES ES19728197T patent/ES2978192T3/es active Active
- 2019-05-14 JP JP2021514291A patent/JP7344959B2/ja active Active
- 2019-05-14 CA CA3100319A patent/CA3100319A1/en active Pending
- 2019-05-14 WO PCT/US2019/032127 patent/WO2019222154A1/en not_active Ceased
- 2019-05-14 CN CN201980047375.4A patent/CN112424192B/zh active Active
- 2019-05-14 PT PT197313745T patent/PT3793992T/pt unknown
- 2019-05-14 KR KR1020207035503A patent/KR102761591B1/ko active Active
- 2019-05-14 AU AU2019269409A patent/AU2019269409B2/en active Active
- 2019-05-14 JP JP2021514292A patent/JP7343571B2/ja active Active
- 2019-05-14 ES ES19731374T patent/ES2984594T3/es active Active
- 2019-05-14 TW TW108116632A patent/TWI798435B/zh active
- 2019-05-14 FI FIEP19728197.5T patent/FI3793995T3/fi active
- 2019-05-14 US US17/055,483 patent/US12258335B1/en active Active
- 2019-05-14 MY MYPI2020005983A patent/MY199200A/en unknown
- 2019-05-14 DK DK19731374.5T patent/DK3793992T3/da active
- 2019-05-14 SI SI201930733T patent/SI3793995T1/sl unknown
- 2019-05-14 SG SG11202011316RA patent/SG11202011316RA/en unknown
- 2019-05-14 CN CN201980047333.0A patent/CN112424186A/zh active Pending
- 2019-05-14 HU HUE19731374A patent/HUE066627T2/hu unknown
- 2019-05-14 US US17/055,459 patent/US11739080B2/en active Active
- 2019-05-14 TW TW108116631A patent/TWI827601B/zh active
- 2019-05-14 HU HUE19728197A patent/HUE066619T2/hu unknown
- 2019-05-14 KR KR1020257002624A patent/KR20250021604A/ko active Pending
- 2019-05-14 LT LTEPPCT/US2019/032131T patent/LT3793995T/lt unknown
- 2019-05-14 FI FIEP19731374.5T patent/FI3793992T3/fi active
- 2019-05-14 PT PT197281975T patent/PT3793995T/pt unknown
- 2019-05-14 SG SG11202011318QA patent/SG11202011318QA/en unknown
- 2019-05-14 WO PCT/US2019/032131 patent/WO2019222157A1/en not_active Ceased
- 2019-05-14 EP EP24150920.7A patent/EP4349332A3/en active Pending
- 2019-05-14 PL PL19728197.5T patent/PL3793995T3/pl unknown
- 2019-05-14 BR BR112020023269-6A patent/BR112020023269A2/pt unknown
- 2019-05-14 AU AU2019270975A patent/AU2019270975B2/en active Active
- 2019-05-14 EP EP24150915.7A patent/EP4335499A3/en active Pending
- 2019-05-14 US US16/411,402 patent/US10851089B2/en active Active
- 2019-05-14 EP EP19731374.5A patent/EP3793992B1/en active Active
- 2019-05-14 DK DK19728197.5T patent/DK3793995T3/da active
- 2019-05-14 TW TW112115526A patent/TWI895726B/zh active
- 2019-05-14 CA CA3100320A patent/CA3100320A1/en active Pending
- 2019-05-14 EP EP19728197.5A patent/EP3793995B1/en active Active
- 2019-05-14 US US16/411,336 patent/US20190352288A1/en not_active Abandoned
-
2023
- 2023-07-06 US US18/347,674 patent/US12215096B2/en active Active
- 2023-08-31 JP JP2023140718A patent/JP2023164905A/ja active Pending
- 2023-09-04 JP JP2023142664A patent/JP7656669B2/ja active Active
-
2024
- 2024-01-18 AU AU2024200323A patent/AU2024200323B2/en active Active
- 2024-12-17 US US18/983,692 patent/US20250115590A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3100319A1 (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
| RU2797558C2 (ru) | Ингибиторы матриксной металлопротеиназы (mmp) и способы их применения | |
| RU2840074C1 (ru) | Ингибиторы матриксной металлопротеиназы (ммр) и способы их применения | |
| HK40107395A (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
| EP4058437B1 (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
| HK40050775B (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
| HK40050775A (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
| HK40050772B (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
| HK40050772A (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240319 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250424 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250509 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250509 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250818 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250821 |